Trial Profile
An Open-label, Randomized, Parallel-Group, Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Infliximab
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics; Registrational
- Sponsors Celltrion
- 17 Oct 2023 Results comparing discontinuation rates due to lack of efficacy during maintenance treatment with infliximab or vedolizumab in patients with Crohn'S Disease (NCT02883452, NOR-SWITCH, PLANETCD, and LIBERTY-CD) infliximab and two RCTs (GEMINI 2 and VISIBLE 2) on vedolizumab, presented at the 31st United European Gastroenterology Week.
- 09 May 2023 Results of post hoc analysis of the Randomised Phase I Ct-P13 Sc study presented at the Digestive Disease Week 2023
- 09 May 2023 Results of studies LIBERTY-UC, NCT02883452, NOR-SWITCH and VISIBLE 1, GEMINI 1, VARSITY; comparing the discontinuation rates due to lack of efficacy between IFX and VDZ, presented at the Digestive Disease Week 2023